Literature DB >> 10800945

Differential regulation of leukemia inhibitory factor-stimulated neuronal gene expression by protein phosphatases SHP-1 and SHP-2 through mitogen-activated protein kinase-dependent and -independent pathways.

J L Bartoe1, N M Nathanson.   

Abstract

The neurally active cytokine leukemia inhibitory factor (LIF) signals through a bipartite receptor complex composed of LIF receptor alpha (LIFR) and gp130. gp130 and LIFR contain consensus binding motifs for the protein tyrosine phosphatase SHP-2 surrounding tyrosines 118 and 115 (Y118 and Y115) of their cytoplasmic domains, respectively. These sites are necessary for maximal activation of mitogen-activated protein kinase (MAPK). Coexpression of catalytically inactive, but not wild-type, SHP-2 reduced LIFR- and gp130-mediated activation of MAPK up to 75%. Conversely, coexpression of the wild-type, but not catalytically inactive, SHP-1, a related phosphatase, reduced activity up to 80%, demonstrating that SHP-2 and SHP-1 have opposing effects on the MAPK pathway. Mutation of Y115 of the cytoplasmic domain of LIFR eliminates receptor-mediated tyrosine phosphorylation of SHP-2. In contrast, SHP-1 association with gp130 and LIFR is constitutive and independent of Y118 and Y115, respectively. SHP-1 has a positive regulatory role on LIF-stimulated vasoactive intestinal peptide (VIP) reporter gene expression in neuronal cells, whereas the effect of SHP-2 is negative. Furthermore, LIF-stimulated MAPK activation negatively regulates this VIP reporter gene induction. SHP-2 also negatively regulates LIF-dependent expression of choline acetyltransferase, but this regulation could be dissociated from its effects on MAPK activation. These data indicate that SHP-1 and SHP-2 are important regulators of LIF-dependent neuronal gene expression via both MAPK-dependent and -independent pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10800945     DOI: 10.1046/j.1471-4159.2000.0742021.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  5 in total

1.  Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice.

Authors:  C Liu; Y Kanamaru; T Watanabe; N Tada; S Horikoshi; Y Suzuki; Z Liu; Y Tomino
Journal:  Clin Exp Immunol       Date:  2015-07-02       Impact factor: 4.330

Review 2.  Leukemia inhibitory factor (LIF).

Authors:  Nicos A Nicola; Jeffrey J Babon
Journal:  Cytokine Growth Factor Rev       Date:  2015-07-04       Impact factor: 7.638

3.  Negative regulation of inflammatory responses by immunoglobulin A receptor (FcαRI) inhibits the development of Toll-like receptor-9 signalling-accelerated glomerulonephritis.

Authors:  T Watanabe; Y Kanamaru; C Liu; Y Suzuki; N Tada; K Okumura; S Horikoshi; Y Tomino
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

4.  Transregulation of leukemia inhibitory [corrected] factor receptor expression and function by growth factors in neuroblastoma cells.

Authors:  Martha D Port; George S Laszlo; Neil M Nathanson
Journal:  J Neurochem       Date:  2008-07-04       Impact factor: 5.372

Review 5.  Leukemia Inhibitory Factor: An Important Cytokine in Pathologies and Cancer.

Authors:  Megan M Jorgensen; Pilar de la Puente
Journal:  Biomolecules       Date:  2022-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.